Clinical Safety

Is This the Paradigm-Shifting Treatment for ITP?
Research & Development Is This the Paradigm-Shifting Treatment for ITP?

For countless individuals living with Immune Thrombocytopenia, the daily reality involves a constant balancing act of managing medication schedules and navigating the persistent threat of dangerously low platelet counts. The prospect of a life free from this chronic treatment burden has long seemed

Ancient Genes and Modern Toxins May Cause Endometriosis
Research & Development Ancient Genes and Modern Toxins May Cause Endometriosis

A groundbreaking pilot study from Bournemouth University suggests that the origins of endometriosis, a debilitating condition affecting one in ten women, may lie in a complex interaction between our ancient genetic heritage and the modern chemical environment. This new hypothesis proposes that

Should Newborns Still Get Hepatitis B Vaccines at Birth?
Management & Regulatory Should Newborns Still Get Hepatitis B Vaccines at Birth?

Imagine a world where a single shot at birth could shield a child from a devastating liver disease, yet the decision to administer it hangs in a delicate balance of science, public opinion, and political will. In the United States, the hepatitis B vaccine, a cornerstone of infant health for over

Lilly Pushes Jaypirca for Wider Use in Leukemia at ASH
Research & Development Lilly Pushes Jaypirca for Wider Use in Leukemia at ASH

Imagine a world where a single drug could shift the trajectory of blood cancer treatment, offering hope to thousands battling chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). At the recent American Society of Hematology (ASH) meeting in Orlando, Eli Lilly thrust its BTK

Roche’s FDA-Cleared Test Revolutionizes Whooping Cough Diagnosis
Management & Regulatory Roche’s FDA-Cleared Test Revolutionizes Whooping Cough Diagnosis

Imagine a world where a persistent, hacking cough in a child could be diagnosed as whooping cough in under 20 minutes, right at the doctor’s office, preventing weeks of uncertainty and potential spread. This scenario is now closer to reality with Roche’s latest FDA-cleared point-of-care test for

Rethinking Aging: Beyond Hallmarks and Current Measures
Research & Development Rethinking Aging: Beyond Hallmarks and Current Measures

Imagine a world where living to 100 is common, yet the decline of mind and body feels just as relentless as it does today—where longer life doesn’t mean slower aging. This paradox lies at the heart of a provocative critique by Dr. Dan Ehninger and Dr. Maryam Keshavarz, published in Genomic

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later